Special Issue

Osteoarthritis and Associated Pain: Molecular Research and Novel Therapeutic Approaches, 2nd Edition

Message from the Guest Editor

Osteoarthritis (OA), the most common form of arthritis, is a leading cause of debilitating pain and disability, affecting more than 32 million people in the US. The prevalence and incidence of OA have been continuously increasing due to increases in lifespan and obesity. This Special Issue aims to present evidence of the potential targets, therapeutic drugs, and nanoformulations, and their mechanisms in treating osteoarthritis and associated pain. We welcome original research and review papers focused on the mechanisms and therapeutic potential of phytochemicals, peptides, and synthetic nanoparticle-based formulations that are engaged in improving osteoarthritic pain in preclinical and clinical studies. Furthermore, we encourage studies using in vivo and in vitro models to explore the mechanisms of action and interactions of nanoformulations with the molecular mediators of oxidative/nitrosative stress caused by osteoarthritic pain conditions.

Guest Editor

Dr. Gurjit Singh Pantheravax, Ames, IA, USA

Deadline for manuscript submissions

closed (30 June 2025)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/225080

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).